CagriSema vs Tirzepatide (and Retatrutide): Research Comparison

CagriSema vs tirzepatide is one of the most frequently searched comparisons in metabolic research, and CagriSema vs retatrutide is close behind. The three are often lined up as if they were versions of the same thing. They are not. CagriSema is shorthand for cagrilintide + semaglutide: two separate molecules acting on two different receptor systems, amylin and GLP-1. Tirzepatide is one molecule acting on two incretin receptors, GIP and GLP-1. Retatrutide is one molecule acting on three receptors: GIP, GLP-1 and glucagon. This guide compares them the way research does, by receptor coverage, and covers what each design lets a model ask. For in-vitro laboratory research only.

CagriSema vs tirzepatide vs retatrutide at a glance

• CagriSema (cagrilintide + semaglutide): two molecules, an amylin-receptor agonist plus a GLP-1 receptor agonist
• Tirzepatide: one molecule, a dual GIP/GLP-1 receptor agonist
• Retatrutide: one molecule, a triple GIP/GLP-1/glucagon receptor agonist
• Shared target: all three engage the GLP-1 receptor
• Read against a GLP-1-only baseline: CagriSema adds an amylin arm, tirzepatide adds a GIP arm, retatrutide adds GIP and glucagon arms

What is CagriSema? Two molecules, two receptor systems

CagriSema is a co-formulation rather than a single compound. Cagrilintide is a synthetic long-acting amylin analog. Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells, and its receptors are built from the calcitonin receptor paired with one of three receptor activity-modifying proteins (RAMP1, RAMP2 or RAMP3). Cagrilintide is described in the literature as acting at these amylin receptors and at the calcitonin receptor itself. Semaglutide is the GLP-1 receptor agonist half: the single-agonist incretin compound the rest of the class is measured against. Eon supplies the pair as the cagrilintide + semaglutide blend; the background is in cagrilintide + semaglutide explained.

Tirzepatide and retatrutide: one molecule, several receptors

Tirzepatide and retatrutide take the opposite approach, engineering several receptor activities into a single peptide chain. Tirzepatide is built on a GIP-based sequence that also activates the GLP-1 receptor, and published pharmacology characterizes it as an imbalanced dual agonist weighted toward the GIP receptor. Retatrutide (LY3437943) extends the design to a third target, the glucagon receptor. In both, the receptor activities are fixed by the sequence: they travel together and cannot be pulled apart by changing a mix. See what is tirzepatide, what is retatrutide and the dual-versus-triple breakdown in tirzepatide vs retatrutide.

CagriSema vs tirzepatide: amylin pathway vs incretin pathway

Set the shared GLP-1 arm aside and the comparison comes down to one question: what second pathway sits next to GLP-1? In CagriSema it is amylin, a receptor system outside the incretin family. In tirzepatide it is GIP, a second incretin receptor. Both second arms are studied in appetite-regulation and glucose-handling models, but they act through different receptor families. Amylin-receptor signaling in the hindbrain, particularly the area postrema, is a recurring focus of rodent appetite-regulation research, while GIP-receptor research centers on insulin secretion and lipid handling.

Cagrilintide semaglutide vs tirzepatide: what each design lets a model ask

A model built around the blend asks how much an amylin-pathway contribution adds to GLP-1 receptor signaling. A model built around tirzepatide asks what dual incretin engagement does that GLP-1 agonism alone does not. Running both next to a semaglutide arm turns the three into a matched set, since all of them engage the GLP-1 receptor and differ only in what sits beside it. The single-versus-dual incretin question on its own is covered in semaglutide vs tirzepatide.

CagriSema vs retatrutide: amylin arm vs glucagon arm

The gap here is wider. Retatrutide shares GLP-1 activity with CagriSema and GIP activity with tirzepatide, then adds the glucagon receptor, which neither of the others engages. CagriSema shares only the GLP-1 arm with it, and its amylin arm has no counterpart in retatrutide. So the comparison runs both ways: retatrutide carries GIP and glucagon arms that CagriSema lacks, and CagriSema carries an amylin arm that retatrutide lacks.

Cagrilintide semaglutide vs retatrutide in energy-expenditure models

The glucagon receptor changes which readouts matter. In research models, glucagon-receptor agonism is examined for its role in energy expenditure and hepatic (liver) metabolism, and the incretin arms of a triple agonist are studied partly as a counterweight to glucagon's effect on hepatic glucose output. A retatrutide model is therefore often built around energy-expenditure and liver readouts, such as indirect calorimetry in rodents. A cagrilintide + semaglutide model is more often built around food-intake and satiety-signaling readouts, the area both the amylin and GLP-1 pathways are most studied in. Comparing them asks whether adding an energy-expenditure pathway or a second appetite-regulation pathway changes the same readouts in a given model.

Two molecules vs one: why the design matters for attribution

The structural difference has a practical consequence. Because CagriSema is two molecules, a design can run the blend next to semaglutide alone and attribute the difference to the cagrilintide component. In a single-molecule agonist the receptor activities are locked into one sequence, so separating the GIP, GLP-1 or glucagon contribution of tirzepatide or retatrutide relies on other tools, such as receptor-knockout animal models or selective receptor antagonists. One caveat for the blend: it is supplied at a fixed, equal-mass ratio of the two compounds, so the ratio is not a variable a lab can change within one preparation.

CagriSema or retatrutide or tirzepatide: matching the compound to the question

None of the three ranks above the others; they answer different questions. A rough guide by research question:

• Amylin-pathway contribution alongside GLP-1 signaling: the cagrilintide + semaglutide blend, with semaglutide alone as the GLP-1 control
• Dual incretin engagement (GIP + GLP-1) within one molecule: tirzepatide
• Glucagon-receptor contribution in energy-expenditure and hepatic-metabolism models: retatrutide, with tirzepatide as the two-receptor comparator
• Receptor coverage across the whole class: semaglutide, tirzepatide, retatrutide and the blend studied as a set

For the full incretin receptor map, see GLP-1 research peptides explained; for the wider collection, see Weight Loss Research Peptides.

Handling and reconstitution

All three ship lyophilized from our US facility with tracking and are reconstituted with bacteriostatic water before in-vitro use; bench technique is in how to reconstitute peptides. Because the blend holds two compounds in one vial, concentration math is per compound: the cagrilintide + semaglutide calculator handles that, alongside the tirzepatide calculator and the retatrutide calculator. Order cagrilintide + semaglutide, tirzepatide or retatrutide directly.